(NewsDirect)
Scancell Holdings PLC (AIM:SCLP,OTC:SCNLF)'s chief executive Professor Lindy Durrant speaks toThomas Warner from Proactive to provide an update on the clinicalstage biopharmaceutical company's progress and financial position.
Durrant starts by highlighting thatScancell has "plenty of money" before going into more detailabout what's been happening with its two lead compounds, SCIB1 andModi-1. She also touches on progress in the relationship with Genmabsince signing a commercial licensing agreement last year, andclarifies that Scancell is continuing to pursue other such deals:"We've just signed an evaluation with a new company... andwe're in current discussions with a second company about anotherpotential deal."
She adds that the company is "wellfinanced" with a runway extending into the second half of 2024,but makes it clear that the continued emergence of promising clinicaldata could make a fundraise necessary - saying that "clearly acompany of our size always needs to think about that as we goforward."
Contact Details
Proactive UKLtd
Proactive UK Ltd
+44 20 7989 0813
Copyright (c) 2023 TheNewswire - All rights reserved.